National Cancer Institute US - Pharmaceuticals & Healthcare - Deals and Alliances Profile

National Cancer Institute US - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH63468D
  • |
  • Pages: 139
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

National Cancer Institute US (NCI), a subsidiary of National Institutes of Health is a provider of cancer research and training services. The institute coordinates National Cancer Program that supports and coordinates research projects in universities, hospitals, research foundations and businesses, and conducts through research grants and cooperative agreements. NCI also supports education and training fundamental sciences and clinical disciplines for holding in basic and clinical research programs and treatment programs related to cancer through career awards, training grants and fellowships. The institute's target therapy areas include leukemia, lymphoma, blood cancer, lung cancer, breast cancer, colorectal cancer and skin cancer, among others. NCI is headquartered in Bethesda, Maryland, the US.

National Cancer Institute US-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 7

National Cancer Institute US, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

National Cancer Institute US, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

National Cancer Institute US, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

National Cancer Institute US, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

National Cancer Institute US, Medical Devices Deals, 2012 to YTD 2018 13

National Cancer Institute US, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

National Cancer Institute US, Pharmaceuticals & Healthcare, Deal Details 18

Partnerships 18

Onconova Therapeutics Enters into R&D Agreement with National Cancer Institute 18

SillaJen Enters into R&D Agreement with National Cancer Institute 19

Xcovery Partners with National Cancer Institute and Children's Oncology Group 20

Cancer Prevention Pharma Enters into Partnership with National Cancer Institute and Vanderbilt University Medical Center 21

Race Oncology Enters into Agreement with National Cancer Institute 22

Eleven Biotherapeutics Enters into R&D Agreement with National Cancer Institute and Astrazeneca 23

Lixte Biotech Enters into R&D Agreement with the National Cancer Institute 24

Pandomedx Enters Into Collaboration with National Cancer Institute 25

Agenus Enters into Agreement with National Cancer Institute 26

Threshold Pharma Enters into Agreement with National Cancer Institute 27

Syndax Pharma Enters into Co-Development Agreement with National Cancer Institute 28

Immunovia to Enter into Agreement with National Cancer Institute 29

Pfizer Enters into Agreement with National Cancer Institute 30

Epizyme Enters into Research Agreement with National Cancer Institute 31

Atrin Pharma Enters into Agreement with National Cancer Institute 32

Riptide Bioscience Enters into Agreement with National Cancer Institute 33

PapGene Enters into Agreement with National Cancer Institute 34

Cellectar Biosciences Enters into Contract with National Cancer Institute 35

University of Pittsburgh Cancer Institute Enters into Contract with National Cancer Institute 36

Advanced Accelerator Applications Enters into Agreement with National Cancer Institute 37

Kite Pharma Enters into R&D Agreement with National Cancer Institute 38

Inovio Pharma Partners with National Cancer Institute and Mayo Clinic 39

Altor BioScience Enters into Co-Development Agreement with National Cancer Institute 40

NantBioScience and NantKwest Enters into R&D Agreement with National Cancer Institute 41

PDS Biotechnology Enters into R&D Agreement with National Cancer Institute 42

OriGene Technologies Enters into Contract with National Cancer Institute 43

SolaranRx Enters into R&D Agreement with National Cancer Institute 44

Kite Pharma Enters into Research and Development Agreement with National Cancer Institute 45

Precision Biologics Enters into R&D Agreement with National Cancer Institute 46

Cancer Targeted Technology Enters into Contract Agreement with National Cancer Institute 47

Cerulean Pharma and AstraZeneca Enter into Research Agreement with National Cancer Institute 48

KIYATEC Enters into Research Contract with National Cancer Institute 49

SuviCa Enters into Contract with National Cancer Institute 50

Galena Biopharma Enters into Agreement with National Cancer Institute 51

Etubics Enters into R&D Agreement with National Cancer Institute 52

Intrexon Enters into R&D Agreement with National Cancer Institute 53

MedImmune Enters into Co-Development Agreement with National Cancer Institute 54

Paradigm Shift Therapeutics Enters into Agreement with National Cancer Institute 55

Nanobiotix Enters Into Co-Development Agreement With National Cancer Institute For NBTX-IV 56

National Cancer Institute Enters Into Co-Development Agreement With Seoul National University Hospital For Proteomic Technologies 57

Kite Pharma Amends R&D Agreement with National Cancer Institute for Cancer Immunotherapy Products 58

Rockland Immunochemicals Enters Into Co-Development Agreement With National Cancer Institute 59

DFH Pharma Enters Into Co-Development Agreement With National Cancer Institute 60

Licensing Agreements 61

Selecta Biosciences Enters into Licensing Agreement with National Cancer Institute 61

Aspyrian Therapeutics Enters Into Licensing Agreement With National Cancer Institute For Near-Infrared Photoimmunotherapy 63

Polyplus-transfection Enters into Licensing Agreeement with NIAID and NCI 64

National Cancer Institute US-Key Competitors 65

National Cancer Institute US-Key Employees 66

National Cancer Institute US-Locations And Subsidiaries 68

Head Office 68

Other Locations & Subsidiaries 68

Recent Developments 69

Corporate Communications 69

Oct 18, 2017: Norman Sharpless sworn in as director of the National Cancer Institute 69

Legal and Regulatory 70

Jan 11, 2017: New Drug Formulary Will Help Expedite Use of Agents in Clinical Trials 70

Government and Public Interest 71

Aug 29, 2018: Sergey Grivennikov Receives National Cancer Institute R01 Grant for Colorectal Cancer Research 71

Aug 29, 2018: Yanis Boumber receives R21 grant from National Cancer Institute to study drug resistance in Lung Cancer 72

Aug 22, 2018: St. Jude achieves consecutive highest rating from National Cancer Institute during Cancer Center renewal grant 73

Aug 17, 2018: Cancer Care and Research Center receives USD 2.3 million to continue cancer research 74

Jul 30, 2018: Rogel Cancer Center awarded USD 33.4M from NCI 75

Jul 18, 2018: Feinstein Institute researcher awarded USD 3.5M to develop bladder cancer care program 76

Jul 17, 2018: USD 26.5 million grant to fund first large-scale study of African-American men with prostate cancer 77

Jun 28, 2018: Modeling the Dynamics of Membrane-bound Mutant RAS to Accelerate Discovery of Novel Drug Targets 78

Jun 27, 2018: 2019 Labor HHS Appropriations Bill Calls For NCI Implemention Of New Pilot Program To Improve Patient Access To Cancer Trials 80

Jun 22, 2018: Case Comprehensive Cancer Center earns 'exceptional' rating, USD 31.9 million in grants for research and education from National Cancer Institute 81

Jun 07, 2018: American Association for Cancer Research Supports Goal of Eliminating HPV-related Cancers in the United States 82

Jun 07, 2018: UCLA partners with nation s top cancer centers to endorse goal of eliminating HPV-related cancers in the United States 83

Jun 07, 2018: Siteman Cancer Center among leading institutions encouraging HPV vaccination 84

Jun 06, 2018: Looking at cancer in a whole new way 85

Jun 04, 2018: College of Nursing Team Receives USD 2.5 Million Grant to Improve Interventions for Cancer Survivors 86

May 31, 2018: Medley Genomics Awarded NCI SBIR to Advance Development of Novel Data Analytics for Personalized Cancer Treatments 87

May 15, 2018: Cleveland Clinic Researcher Receives USD 2M Grant to Study Role of Cancer's Genetic Composition in Predicting the Effectiveness of Radiation Therapy 88

Apr 11, 2018: NIH study revises molecular classification for most common type of lymphoma 89

Mar 29, 2018: VTCRI scientist awarded USD 2 million National Cancer Institute grant to study breast cancer 90

Mar 15, 2018: USD 7 million grants boost functional genomics team science 91

Mar 02, 2018: Virus-like particle could lead to new cancer vaccine 92

Feb 05, 2018: Tosk has been awarded a USD 2 million grant from National Cancer Institute to continue the company's TK-kRAS research program 93

Jan 29, 2018: Huntsman Cancer Institute Selected as a National Cancer Institute Center for Patient-Derived Model Development 94

Jan 25, 2018: Cancer researchers hit a bullseye with a new drug target for Ewing sarcoma 95

Jan 16, 2018: Bright light therapy improves sleep in people treated for cancer 97

Jan 12, 2018: Sci-Engi-Medco Solutions Awarded SBIR Phase 1 NCI Contract to Study Its Lead Molecules in Preclinical Model of Triple Negative Breast Cancer 98

Jan 08, 2018: NCI Awards ICF Two Major BPAs to Support Cancer Content, Communications and Web Development Activities 99

Dec 06, 2017: UH Cancer Researcher Focused on Tumor Development 100

Nov 20, 2017: Clinical trial suggests new cell therapy for relapsed leukemia patients 102

Nov 20, 2017: Pairing cancer genomics with cognitive computing highlights potential therapeutic options 104

Nov 14, 2017: A New Strategy for Prevention of Liver Cancer Development 106

Oct 18, 2017: Globus expands data services to accelerate secure cancer research 107

Oct 13, 2017: With USD 3M grant from Stand Up to Cancer, UCLA researcher to advance understanding of how a promising new combination therapy could overcome melanoma resistance to immunotherapy 108

Sep 26, 2017: NCI renews lymphoma immunotherapy research grant 109

Sep 26, 2017: Champions Oncology announces USD 2 million award from the National Cancer Institute to develop and evaluate prostate cancer PDX models 110

Sep 20, 2017: Brain cancer growth halted by absence of protein 111

Sep 19, 2017: Roswell Park Draws More Than USD 6.8 Million for Research on New Treatments and Supportive-Care Approaches 113

Aug 24, 2017: Research reveals how estrogen regulates gene expression 114

Aug 23, 2017: DNA sensor plays critical role in cancer immunotherapy via robust response to unexpected form of DNA 115

Aug 07, 2017: NCI study identifies essential genes for cancer immunotherapy 117

Aug 07, 2017: SignalRx Awarded USD 2M Phase II STTR Grant from the National Cancer Institute for the Development of Epigenetic-Kinase Inhibitors as Anticancer Agents 118

Jul 13, 2017: Several Fox Chase Cancer Center and Temple Health Research Projects Awarded Funding Support Grants 119

Jun 21, 2017: OMRF receives new grants to study blood clotting, ovarian cancer 120

Jun 08, 2017: Fred Hutch epidemiologists receive USD 2.5M grant for first-ever study of therapeutic use for HPV vaccine 121

May 30, 2017: Huntsman Cancer Institute at the University of Utah Selected to Join National Cancer Institute's Systems Biology Consortium 122

May 25, 2017: OHSU Knight Cancer Institute selected to join prestigious national consortium, receive USD 9.2 million 123

Apr 19, 2017: CRT pioneer fund, Cancer Research UK and NCI collaborate to boost research against the 'undruggable' RAS 124

Apr 13, 2017: Brownson awarded USD 2.6 million grant for cancer research 125

Feb 07, 2017: New assay shows promise to advance personalized therapy for cancer patients 126

Jan 13, 2017: Scientists reprogram embryonic stem cells to expand their potential cell fates 127

Jan 12, 2017: Huntsman Cancer Institute Research Holds Promise for Personalized Lung Cancer Treatments 129

Product News 130

Jul 24, 2017: NCI-COG Pediatric MATCH trial to test targeted drugs in childhood cancers 130

Jun 04, 2018: NCI-MATCH precision medicine clinical trial releases new findings, strengthens path forward for targeted cancer therapies 132

Jan 19, 2017: Northwestern University: Clinical Trials Evaluate New Treatment for Anal Cancer 134

Jan 11, 2017: The Wistar Institute and Nation's Cancer Centers Jointly Endorse Updated HPV Vaccine Recommendations 135

Other Significant Developments 136

Sep 26, 2017: Uninsured cancer patients saw increased coverage for care following Medicaid expansion 136

Jun 20, 2017: Grand Valley Oncology Announces Clinical Trials Open to Patients 137

Jan 11, 2017: CSHL joins NCI-designated cancer centers in endorsing updated HPV vaccination recommendations 138

Appendix 139

Methodology 139

About GlobalData 139

Contact Us 139

Disclaimer 139

List of Figures

National Cancer Institute US, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

National Cancer Institute US, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

National Cancer Institute US, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

National Cancer Institute US, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

National Cancer Institute US, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

National Cancer Institute US, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9

National Cancer Institute US, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

National Cancer Institute US, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11

National Cancer Institute US, Medical Devices Deals, 2012 to YTD 2018 13

List of Tables

National Cancer Institute US, Pharmaceuticals & Healthcare, Key Facts 2

National Cancer Institute US, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8

National Cancer Institute US, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9

National Cancer Institute US, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10

National Cancer Institute US, Deals By Therapy Area, 2012 to YTD 2018 11

National Cancer Institute US, Medical Devices Deals, 2012 to YTD 2018 13

National Cancer Institute US, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14

Onconova Therapeutics Enters into R&D Agreement with National Cancer Institute 18

SillaJen Enters into R&D Agreement with National Cancer Institute 19

Xcovery Partners with National Cancer Institute and Children's Oncology Group 20

Cancer Prevention Pharma Enters into Partnership with National Cancer Institute and Vanderbilt University Medical Center 21

Race Oncology Enters into Agreement with National Cancer Institute 22

Eleven Biotherapeutics Enters into R&D Agreement with National Cancer Institute and Astrazeneca 23

Lixte Biotech Enters into R&D Agreement with the National Cancer Institute 24

Pandomedx Enters Into Collaboration with National Cancer Institute 25

Agenus Enters into Agreement with National Cancer Institute 26

Threshold Pharma Enters into Agreement with National Cancer Institute 27

Syndax Pharma Enters into Co-Development Agreement with National Cancer Institute 28

Immunovia to Enter into Agreement with National Cancer Institute 29

Pfizer Enters into Agreement with National Cancer Institute 30

Epizyme Enters into Research Agreement with National Cancer Institute 31

Atrin Pharma Enters into Agreement with National Cancer Institute 32

Riptide Bioscience Enters into Agreement with National Cancer Institute 33

PapGene Enters into Agreement with National Cancer Institute 34

Cellectar Biosciences Enters into Contract with National Cancer Institute 35

University of Pittsburgh Cancer Institute Enters into Contract with National Cancer Institute 36

Advanced Accelerator Applications Enters into Agreement with National Cancer Institute 37

Kite Pharma Enters into R&D Agreement with National Cancer Institute 38

Inovio Pharma Partners with National Cancer Institute and Mayo Clinic 39

Altor BioScience Enters into Co-Development Agreement with National Cancer Institute 40

NantBioScience and NantKwest Enters into R&D Agreement with National Cancer Institute 41

PDS Biotechnology Enters into R&D Agreement with National Cancer Institute 42

OriGene Technologies Enters into Contract with National Cancer Institute 43

SolaranRx Enters into R&D Agreement with National Cancer Institute 44

Kite Pharma Enters into Research and Development Agreement with National Cancer Institute 45

Precision Biologics Enters into R&D Agreement with National Cancer Institute 46

Cancer Targeted Technology Enters into Contract Agreement with National Cancer Institute 47

Cerulean Pharma and AstraZeneca Enter into Research Agreement with National Cancer Institute 48

KIYATEC Enters into Research Contract with National Cancer Institute 49

SuviCa Enters into Contract with National Cancer Institute 50

Galena Biopharma Enters into Agreement with National Cancer Institute 51

Etubics Enters into R&D Agreement with National Cancer Institute 52

Intrexon Enters into R&D Agreement with National Cancer Institute 53

MedImmune Enters into Co-Development Agreement with National Cancer Institute 54

Paradigm Shift Therapeutics Enters into Agreement with National Cancer Institute 55

Nanobiotix Enters Into Co-Development Agreement With National Cancer Institute For NBTX-IV 56

National Cancer Institute Enters Into Co-Development Agreement With Seoul National University Hospital For Proteomic Technologies 57

Kite Pharma Amends R&D Agreement with National Cancer Institute for Cancer Immunotherapy Products 58

Rockland Immunochemicals Enters Into Co-Development Agreement With National Cancer Institute 59

DFH Pharma Enters Into Co-Development Agreement With National Cancer Institute 60

Selecta Biosciences Enters into Licensing Agreement with National Cancer Institute 61

Aspyrian Therapeutics Enters Into Licensing Agreement With National Cancer Institute For Near-Infrared Photoimmunotherapy 63

Polyplus-transfection Enters into Licensing Agreeement with NIAID and NCI 64

National Cancer Institute US, Key Competitors 65

National Cancer Institute US, Key Employees 66

National Cancer Institute US, Other Locations 68

National Cancer Institute US, Subsidiaries 68

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

National Cancer Institute US, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17810
Site License
USD 500 INR 35620
Corporate User License
USD 750 INR 53430

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com